期刊文献+

体外冲击波辅助依托考昔治疗早中期膝骨关节炎临床观察 被引量:2

下载PDF
导出
摘要 目的观察体外冲击波(ESW)辅助依托考昔治疗早中期膝骨关节炎(KOA)的临床效果。方法选择早中期KOA患者70例,随机分为观察组和对照组,每组35例。两组均给予口服依托考昔治疗,60 mg/次、1次/d,连续治疗6周。观察组在此基础上给予ESW治疗,冲击频率6 Hz,治疗能流密度0.2 mJ/mm^2,单侧膝关节冲击4000次,每次治疗3~5 min,每周1次,共6次。治疗6周,评价临床疗效。治疗前与治疗6周,采用WOMAC评分、Lequene-Mery评分评价膝关节功能;收集清晨空腹肘静脉血,离心留取上层血清,采用ELISA法检测血清IL-1β、TNF-α,采用免疫比浊法检测血清hs-CRP。结果治疗过程中,观察组脱落2例、对照组脱落1例,最终观察组纳入33例、对照组纳入34例。治疗6周,观察组总有效率为96.97%(32/33),对照组为91.18%(31/34),两组总有效率比较P<0.05。两组治疗后WOMAC评分、Lequene-Mery评分均低于治疗前,且观察组治疗后WOMAC评分、Lequene-Mery评分均低于对照组治疗后(P均<0.05)。两组治疗后血清IL-1β、TNF-α、hs-CRP水平均低于治疗前,且观察组治疗后血清IL-1β、TNF-α、hs-CRP水平均低于对照组治疗后(P均<0.05)。结论ESW辅助依托考昔能够明显改善早中期KOA患者膝关节功能,降低血清炎症细胞因子水平,其临床效果优于单用依托考昔。
出处 《山东医药》 CAS 2020年第22期60-62,共3页 Shandong Medical Journal
基金 河南省科技发展计划(172102310650)。
  • 相关文献

参考文献11

二级参考文献37

  • 1Takemoto JK, Peynolds JK, Remsberg CM, et al. Clinical pharmacokinetic and pharmaco-dynamic profile of etoricoxib. Clin Pharmacokinet, 2008, 47:703-720.
  • 2Curtis SP, Bockow B, Fisher C, et 81. Etoricoxib in the trea- tment of osteoarthritis over 52-weeks: a double-blind, active- comparator controlled trial [ NCT00242489 ]. BMC Musculoskelet Disord, 2005, 6: 58.
  • 3Zhang W, Doherty M, Arden N, et al. EULAR evidence based recommendations for the management of hip osteoarhritis: report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis, 2005, 64: 669-681.
  • 4Jordan KM, AMen NK, Doherty M, et al. EULAR recommen- dations 2003: an evidence based approach to the management of knee osteoarthritis: report of a Task Force of the Standing Committee for International Clinical Studies Including Thera- peutic Trials (ESCISIT). Ann Rheum Dis, 2003, 62: 1145- 1155_.
  • 5Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update. American College of Rheumato- logy Subcommittee on Osteoarthritis Guidelines. Arthritis Rheum, 2000, 43: 1905-1915.
  • 6Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidalantiinflammatory drugs. N Engl J Med, 1999, 340: 1888-1899.
  • 7Gottesdiener K, Schnitzer T, Fisher C, et al. Results of a randomized, dose-ranging trial of etoricoxib in patients with osteoarthritis. Rheumatology, 2002, 41 : 1052-1061.
  • 8Bingharn CO 3rd, Sebba AI, Rubin BR, et al. Efficacy and safety of etoricoxib 30 mg and celecoxib 200 nag in the treatment of osteoarthritis in two identically designed, randomized, place- boeontrolled, non-inferiority studies. Rheumatology (Oxford), 2007, 46: 496-507.
  • 9Leung AT, Malmstrom K, Gallacher AE, et al. Efficacy and tolerability profile of etoricoxib in patients with osteoarthritis: a randomized, double-blind, placebo and active-comparator controlled 12-week efficacy triM. Curr Med Res Opin, 2002, 18: 49-58.
  • 10Zacher J, Feldman D, Gerli R, et al. A comparison of the therapeutic efficacy and tolerability of etoricoxib and diclofenac in patients with osteoarthritis. Curr Med Res Opin, 2003, 19: 725-736.

共引文献1543

同被引文献17

引证文献2

二级引证文献19

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部